{
    "root": "04b0d213-8194-475d-b18d-00b2d048c9dc",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "SPIRONOLACTONE",
    "value": "20250311",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "DOCUSATE SODIUM",
            "code": "F05Q2T2JA0"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "SPIRONOLACTONE",
            "code": "27O7W4T232"
        }
    ],
    "indications": "spironolactone tablets aldosterone antagonist indicated : \u2022 treatment nyha class iii-iv heart failure reduced ejection fraction increase survival , manage edema , reduce need hospitalization heart failure ( 1.1 ) . \u2022 add-on therapy treatment hypertension , lower blood pressure . lowering blood pressure reduces risk fatal nonfatal cardiovascular events , primarily strokes myocardial infarctions ( 1.2 ) . \u2022 management edema adult patients cirrhotic edema responsive fluid sodium restrictions setting nephrotic syndrome treatment underlying disease , restriction fluid sodium intake , diuretics produce inadequate response ( 1.3 ) . \u2022 treatment primary hyperaldosternism : ( 1.4 ) . \u2022 short-term preoperative treatment \u2022 long-term maintenance patients discrete aldosterone-producing adrenal adenomas candidates surgery patients bilateral micro macronodular adrenal hyperplasia",
    "contraindications": "\u2022 heart failure : initiate treatment 25 mg daily ( 2.2 ) . \u2022 hypertension : initiate treatment 25 100 mg daily either single divided doses ( 2.3 ) . \u2022 edema : initiate therapy hospital setting titrate slowly . recommended initial daily dose 100 mg single divided doses ( 2.4 ) . \u2022 primary hyperaldosteronism : initiate treatment 100 400 mg preparation surgery . patients unsuitable surgery lowest effective determined individual patient ( 2.5 ) .",
    "warningsAndPrecautions": "spironolactone tablets , usp supplied follows : spironolactone tablets 25 mg , white , round , unscored , debossed mp 35 ndc 72162-1624-1 bottles 100 ndc 72162-1624-3 bottles 30 ndc 72162-1624-5 bottles 500 \ufeffndc 72162-1624-6 bottles 60 ndc 72162-1624-9 bottles 90 ndc 72162-1624-0 bottles 1000 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature ] dispense tight , light-resistant container . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "spironolactone tablets contraindicated patients : \u2022hyperkalemia \u2022addison \u2019 disease \u2022concomitant eplerenone",
    "indications_original": "Spironolactone tablets are an aldosterone antagonist indicated for: \u2022 The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). \u2022 Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). \u2022 The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). \u2022 Treatment of primary hyperaldosternism for: ( 1.4 ). \u2022 Short-term preoperative treatment \u2022 Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia",
    "contraindications_original": "\u2022 Heart Failure: Initiate treatment at 25 mg once daily ( 2.2 ). \u2022 Hypertension: Initiate treatment at 25 to 100 mg daily in either single or divided doses ( 2.3 ). \u2022 Edema: Initiate therapy in a hospital setting and titrate slowly. The recommended initial daily dose is 100 mg in single or divided doses ( 2.4 ). \u2022 Primary hyperaldosteronism: Initiate treatment at 100 to 400 mg in preparation for surgery. In patients unsuitable for surgery use the lowest effective dosage determined for the individual patient ( 2.5 ).",
    "warningsAndPrecautions_original": "Spironolactone tablets, USP are supplied as follows:\n                  Spironolactone tablets 25 mg, white, round, unscored, debossed MP 35\n                  NDC 72162-1624-1 Bottles of 100\u00a0\n                  NDC 72162-1624-3 Bottles of 30\n                  NDC 72162-1624-5 Bottles of 500\u00a0 \u00a0\n                  \ufeffNDC 72162-1624-6 Bottles of 60\n                  NDC 72162-1624-9 Bottles of 90\n                  NDC 72162-1624-0 Bottles of 1000\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F).\n                  [See USP Controlled Room Temperature]\n                  DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Spironolactone tablets are contraindicated in the patients with:\n                  \n                     \n                        \u2022Hyperkalemia        \n                     \n                        \u2022Addison\u2019s disease        \n                     \n                        \u2022Concomitant use of eplerenone"
}